Search
Bioventus Inc
BVSAdd to Watchlist
10.480USD
+0.630+6.40%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
708.86MMarket Cap
24.52P/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+6.40%
5 Days
+7.16%
1 Month
+20.46%
6 Months
+45.35%
Year to Date
+40.86%
1 Year
+49.29%
Key Figures
9.968Open
10.489High
701.20KVolume
24.52P/E TTM
10.00P/E Dynamic
--Dividend TTM
1.04%Turnover Ratio
9.850Prev. Close
9.880Low
5.19MTurnover
LossP/E Static
3.75P/B
0.00%Div Yield TTM
5.15%ROA
11.24952wk High
1.43Volume Ratio
-33.54MNet Profit
67.64MShares
0.4274EPS TTM
0.69Beta
16.90%ROE
5.81052wk Low
6.18%Amplitude
67.88%Gross Margin
708.86MMarket Cap
4.56Reward/Risk
2.90%Risk Rate
TradingKey Stock Score of Bioventus Inc
Currency: USD Updated: 2026-07-02Key Insights
Bioventus Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 49 out of 204 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 14.80.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Bioventus Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
Bioventus Inc Highlights
StrengthsRisks
Bioventus Inc. is a medical device company. The Company’s portfolio of products is grouped into three areas. Its Pain Treatments include the Knee Osteoarthritis (KOA) area, and Peripheral Nerve Stimulation (PNS) area. Its Surgical Solutions include Ultrasonics, which offers precision bone resection for patients with degenerative spine conditions and spinal deformities, and Bone Graft Substitutes (BGS), which includes a range of products that facilitate optimal bone fusion following a surgical procedure. Its Restorative Therapies comprise Fracture Care that provide low-intensity pulse ultrasound to help patients who suffer from bone fractures that do not heal through traditional methods. It offers a diverse portfolio of products to support physicians in relieving pain and addressing musculoskeletal challenges across indications and clinical areas, including knee, hand and upper extremities, foot and ankle, podiatry, trauma, general surgery, spine and neurosurgery.
Turnaround to Profit
The company's performance has turned profitable, with the latest annual net income of USD .
Overvalued
The company’s latest PE is 24.52, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 52.51M shares, decreasing 16.27% quarter-over-quarter.
Held by Chuck Royce
Star Investor Chuck Royce holds 1.58M shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.66.
Analyst Rating
Based on
5
analysts
Buy
Current Rating
14.800
Target Price
+50.25%
Upside Space
Bioventus Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Bioventus Inc Info
Bioventus Inc. is a medical device company. The Company’s portfolio of products is grouped into three areas. Its Pain Treatments include the Knee Osteoarthritis (KOA) area, and Peripheral Nerve Stimulation (PNS) area. Its Surgical Solutions include Ultrasonics, which offers precision bone resection for patients with degenerative spine conditions and spinal deformities, and Bone Graft Substitutes (BGS), which includes a range of products that facilitate optimal bone fusion following a surgical procedure. Its Restorative Therapies comprise Fracture Care that provide low-intensity pulse ultrasound to help patients who suffer from bone fractures that do not heal through traditional methods. It offers a diverse portfolio of products to support physicians in relieving pain and addressing musculoskeletal challenges across indications and clinical areas, including knee, hand and upper extremities, foot and ankle, podiatry, trauma, general surgery, spine and neurosurgery.
Ticker SymbolBVS
CompanyBioventus Inc
CEOClaypoole (Robert E)
Websitehttps://www.bioventus.com/
Related Instruments
-0.37%
+1.91%
+3.48%
+5.87%
+2.10%
-0.10%
+4.19%
+5.03%
+4.30%
+0.25%
+3.65%
+4.74%
+2.79%
+2.59%
-3.06%
+3.40%
+3.76%
+1.10%
+0.28%
-2.09%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of Bioventus Inc (BVS)?
The current price of Bioventus Inc (BVS) is 10.48.
What is the symbol of Bioventus Inc?
The ticker symbol of Bioventus Inc is BVS.
What is the 52-week high of Bioventus Inc?
The 52-week high of Bioventus Inc is 11.25.
What is the 52-week low of Bioventus Inc?
The 52-week low of Bioventus Inc is 5.81.
What is the market capitalization of Bioventus Inc?
The market capitalization of Bioventus Inc is 708.86M.
Is Bioventus Inc (BVS) currently rated as Buy, Hold, or Sell?
According to analysts, Bioventus Inc (BVS) has an overall rating of Buy, with a price target of 14.80.
What is the Earnings Per Share (EPS TTM) of Bioventus Inc (BVS)?
The Earnings Per Share (EPS TTM) of Bioventus Inc (BVS) is 0.34.